Navigation Links
FDA Mislead On Asthma Drug By GlaxoSmithKline

Charges have been held against, a London based leading drug company, GlaxoSmithKline for having presented incorrect data regarding an anti-asthmatic drug, Serevent to the U.S. Food and Drug Administration two years ago when the // medicine came up for a review. This became evident last November when The FDA identified Serevent as a drug that needed additional warnings.

The Public Citizen Group has registered a case regarding the issue. The company is said to have manipulated from the so-called SMART trial, which was initiated in 1996. The study was conducted on a group of asthma patients for 28 weeks who received either Serevent, also known as salmeterol, or a placebo. An increased risk of asthma-related death in those who had consumed the drug has been documented.

However, Glaxo is said to have misled the FDA when it submitted six months of post- trial data in July 2003, along with the study's actual 28 weeks of data. There is a belief that the data presented is an underestimated projection of the apparent dangers associated with salmeterol, including asthma related death. The SMART data has never been published.

``GlaxoSmithKline did not clearly inform the FDA that the final study included data from six months after the trial had concluded until the FDA inquired about the results in April, 2004,'' according to those who have filed the case.

The company in response has issued a statement stating that the SMART study data were collected and analyzed by an independent clinical research organization, not by them.

“After discussions with the Data Safety Monitoring Board, Glaxo was provided with unmasked results of the interim analysis and subsequently terminated the study. The SMART trial was stopped on Jan. 23, 2003, a “Dear Healthcare Professional letter'' was delivered overnight to all U.S. doctors who had prescribed salmeterol, and notices were posted on both the FDA and Glaxo websites,'' said Mr. Kathy Rick ard of Glaxo's Respiratory Medicines Development Center in Research Triangle Park, North Carolina.

Salmeterol is a key ingredient in Serevent and is combined with a steroid to make up Advair, both of which work by easing constriction in the lungs of asthma sufferers. Serevent and Advair together outsell competing asthma treatments as well as Glaxo's other products. The drugs' sales last year totalled 2.5 billion pounds (about $4.4 billion.
'"/>




Related medicine news :

1. Misleading anti-malarial drug
2. Misleading Advertisements for Prescription Drugs
3. The Effects Of Smoking Misleading
4. Lifting The Screen off Misleading Sunscreen labels
5. Misleading Health Claims On Food Labels No Longer Allowed in EU
6. Walkers Crisps Advertisements make Misleading Claims about Salt Content
7. Medical Council Of India Draws Public Attention on Misleading Ads.
8. Obesity Drug Advertisements Misleading Teens
9. Labeling of Dairy Products with Trans fat labels, Misleading to Consumers
10. New Drug for Bronchial Asthma
11. Asthma may actually be prevented by Dust and Dirt
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
Breaking Medicine Technology: